Literature DB >> 3606084

In vitro susceptibility of Citrobacter species to various antimicrobial agents.

G Samonis, D H Ho, G F Gooch, K V Rolston, G P Bodey.   

Abstract

The in vitro activities of 16 antimicrobial agents against 14 clinical isolates of Citrobacter diversus and 27 isolates of Citrobacter freundii were studied. C. freundii isolates were more resistant, being susceptible only to amikacin, netilmicin, gentamicin, imipenem, ciprofloxacin, and enoxacin. C. diversus isolates were susceptible to many more of the agents tested.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3606084      PMCID： PMC174846          DOI： 10.1128/AAC.31.5.829

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.

Authors:  G P Bodey; M Buckley; Y S Sathe; E J Freireich
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

2.  In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.

Authors:  I Garcia; G P Bodey; V Fainstein; D H Ho; B LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

3.  Comparative in vitro study of SQ26,776.

Authors:  V Fainstein; S Weaver; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Bacteremias due to Citrobacter diversus and Citrobacter freundii. Incidence, risk factors, and clinical outcome.

Authors:  V Drelichman; J D Band
Journal:  Arch Intern Med       Date:  1985-10

5.  In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.

Authors:  M Toda; N Arao; C Nohara; K Susaki; A Tachibana
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

6.  Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  Clinical significance of citrobacter isolates.

Authors:  G R Hodges; C E Degener; W G Barnes
Journal:  Am J Clin Pathol       Date:  1978-07       Impact factor: 2.493

Review 8.  Citrobacter infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature.

Authors:  B A Lipsky; E W Hook; A A Smith; J J Plorde
Journal:  Rev Infect Dis       Date:  1980 Sep-Oct

9.  In vitro activity of BRL 36650, a new semisynthetic penicillin.

Authors:  J F Hoy; K V Rolston; D H Ho; M Alvarez; P Thirolf; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

10.  In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.

Authors:  G M Eliopoulos; A E Moellering; E Reiszner; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191
View more
  10 in total

1.  Citrobacter brain abscesses in neonates: early surgical intervention and review of the literature.

Authors:  Shakeel A Chowdhry; Alan R Cohen
Journal:  Childs Nerv Syst       Date:  2012-04-15       Impact factor: 1.475

2.  Multidrug resistant citrobacter: an unusual cause of liver abscess.

Authors:  Prabhat Kumar; Soumik Ghosh; Deepak Rath; A K Gadpayle
Journal:  BMJ Case Rep       Date:  2013-04-22

3.  Citrobacter infections in a general hospital: characteristics and outcomes.

Authors:  G Samonis; D E Karageorgopoulos; D P Kofteridis; D K Matthaiou; V Sidiropoulou; S Maraki; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-06       Impact factor: 3.267

Review 4.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

5.  Review of Citrobacter bacteremia in cancer patients over a sixteen-year period.

Authors:  G Samonis; E Anaissie; L Elting; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 7.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

8.  Complete Genome Sequence of Citrobacter freundii Myophage Moon.

Authors:  Garrett B Edwards; Adrian J Luna; Adriana C Hernandez; Gabriel F Kuty Everett
Journal:  Genome Announc       Date:  2015-01-29

9.  Community-Acquired Pneumonia and Empyema Caused by Citrobacter koseri in an Immunocompetent Patient.

Authors:  Miguel Angel Ariza-Prota; Ana Pando-Sandoval; Marta García-Clemente; Ramón Fernández; Pere Casan
Journal:  Case Rep Pulmonol       Date:  2015-11-08

10.  Comparative Genomic Analysis of Citrobacter and Key Genes Essential for the Pathogenicity of Citrobacter koseri.

Authors:  Chao Yuan; Zhiqiu Yin; Junyue Wang; Chengqian Qian; Yi Wei; Si Zhang; Lingyan Jiang; Bin Liu
Journal:  Front Microbiol       Date:  2019-12-06       Impact factor: 5.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.